Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: Preparation and in vitro study

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1851-1863

  Hosseinzadeh, Hosniyeh ^a   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a   Ostad, Seyed Naser ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anticancer; Chitosan; Gemcitabine; Ionic gelation; Mucoadhesion; Nanoparticles; Oral drug delivery

Indexed keywords

CHITOSAN; GEMCITABINE; MUCIN; NANOPARTICLE; POLOXAMER; TRIPOLYPHOSPHATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DIFFERENTIAL SCANNING CALORIMETRY; DNA BASE COMPOSITION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STRUCTURE; GELATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MOLECULAR INTERACTION; MUCOADHESION; NANOANALYSIS; NANOENCAPSULATION; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; STRUCTURE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

CELL SURVIVAL; CHITOSAN; DEOXYCYTIDINE; DRUG CARRIERS; HT29 CELLS; HUMANS; MUCINS; NANOPARTICLES; PARTICLE SIZE; POLOXAMER;

EID: 84870360366     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S26365     Document Type: Article

References (52)

1. Suri S, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2(1):16.
2. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58(2): 97-110.
3. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8):583-592.
4. Yousefpour P, Atyabi F, Vasheghani Farahani E, Sakhtianchi R, Dinarvand R. Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int J Nanomedicine. 2011;6:1487-1496.
5. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
6. Cuenca AG, Jiang H, Hochwald SN, et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107(3):459-466.
7. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100(1):5-28.
8. Calvo P, Remuñán López C, Vila Jato J, Alonso M. Novel hydrophilic chitosan polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63(1):125-132.
9. Shah S, Pal A, Kaushik V, Devi S. Preparation and characterization of venlafaxine hydrochloride loaded chitosan nanoparticles and in vitro release of drug. J Appl Polym Sci. 2009;112(5):2876-2887.
10. Atyabi F, Talaie F, Dinarvand R. Thiolated chitosan nanoparticles as an oral delivery system for amikacin: in vitro and ex vivo evaluations. J Nanosci Nanotechnol. 2009;9(8):4593-4603.
11. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomedicine. 2011;6:119-128.
12. Pan Y, Li Y, Zhao H, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm. 2002;249(1-2):139-147.
13. Talasaz AHH, Ghahremankhani AA, Moghadam SH, et al. In situ gel forming systems of poloxamer 407 and hydroxypropyl cellulose or hydroxypropyl methyl cellulose mixtures for controlled delivery of vancomycin. J Appl Polym Sci. 2008;109(4):2369-2374.
14. Taheri A, Atyabi F, Dinarvnd R. Temperature-responsive and biodegradable PVA: PVP k30: poloxamer 407 hydrogel for controlled delivery of human growth hormone (hGH). J Pediatr Endocrinol Metab. 2011;24(3-4):175-179.
15. Mortensen K. Block copolymer in aqueous solution: Micelle formation and hard-sphere crystallization. Trends in Colloid and Interface Science VII. 1993:72-75.
16. Zhou Z, Chu B. Light-scattering study on the association behavior of triblock polymers of ethylene oxide and propylene oxide in aqueous solution. J Colloid Interf Sci. 1988;126(1):171-180.
17. Wanka G, Hoffmann H, Ulbricht W. The aggregation behavior of poly-(oxyethylene)-poly-(oxypropylene)-poly-(oxyethylene)-block-copolymers in aqueous solution. Colloid Polym Sci. 1990;268(2):101-117.
18. Bohorquez M, Koch C, Trygstad T, Pandit N. A study of the temperature-dependent micellization of Pluronic F127. J Colloid Interf Sci. 1999;216(1):34-40.
19. Cabana A, Aït-Kadi A, Juhász J. Study of the gelation process of polyethylene oxidea-polypropylene oxideb-polyethylene oxideacopolymer (poloxamer 407) aqueous solutions. J Colloid Interf Sci. 1997;190(2):307-312.
20. Wenzel JGW, Balaji K, Koushik K, et al. Pluronic® F127 gel formulations of Deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release. 2002;85(1-3):51-59.
21. Veyries M, Couarraze G, Geiger S, et al. Controlled release of vancomycin from poloxamer 407 gels. Int J Pharm. 1999;192(2):183-193.
22. Reddy LH, Dubernet C, Mouelhi SL, et al. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release. 2007;124(1-2):20-27.
23. Immordino ML, Brusa P, Rocco F, et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release. 2004;100(3):331-346.
24. Grinberg O, Gedanken A, Patra CR, et al. Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta Biomater. 2009;5(8):3031-3037.
25. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58(19):4349.
26. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrativesensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000;60(21):6075.
27. Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des. 2008;14(11):1124-1137.
28. Trickler WJ, Khurana J, Nagvekar AA, Dash AK. Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment. AAPS PharmSciTech. 2010;11(1):392-401.
29. Arias JL, Reddy LH, Couvreur P. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J of Drug Target. 2009;17(8):586-598.
30. Wang CX, Huang LS, Hou LB, et al. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain research. 2009;1261:91-99.
31. Patra CR, Bhattacharya R, Wang E, et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008;68(6):1970-1978.
32. Gang J, Park SB, Hyung W, et al. Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target. 2007;15(6):445-453.
33. Moghaddam FA, Atyabi F, Dinarvand R. Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine. 2009;5(2):208-215.
34. Akhlaghi SP, Saremi S, Ostad SN, Dinarvand R, Atyabi F. Discriminated effects of thiolated chitosan-coated pMMA paclitaxelloaded nanoparticles on different normal and cancer cell lines. Nanomedicine. 2010;6(5):689-697.
35. Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohyd Polym. 2008;73(1):44-54.
36. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm. 1998;166(1): 75-88.
37. MacLaughlin FC, Mumper RJ, Wang J, et al. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release. 1998;56(1-3):259-272.
38. Ajun W, Yan S, Li G, Huili L. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohyd Polym. 2009;75(4):566-574.
39. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115(2):216-225.
40. Zheng Y, Wu Y, Yang W, et al. Preparation, characterization, and drug release in vitro of chitosan glycyrrhetic acid nanoparticles. J Pharm Sci. 2006;95(1):181-191.
41. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerf. 2007;59(1):24-34.
42. Ajun W, Yan S, Li G, Huili L. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohyd Polym. 2009;75(4):566-574.
43. Rokhade AP, Shelke NB, Patil SA, Aminabhavi TM. Novel hydrogel microspheres of chitosan and pluronic F-127 for controlled release of 5-fluorouracil. J Microencapsul. 2007;24(3):274-288.
44. Cho CW, Shin S, Oh IJ. Thermorheologic properties of aqueous solutions and gels of poloxamer 407. Drug Dev Ind Pharm. 1997;23(12):1227-1232.
45. Wu Y, Yang W, Wang C, Hu J, Fu S. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm. 2005;295(1-2):235-245.
46. Rokhade AP, Shelke NB, Patil SA, Aminabhavi TM. Novel hydrogel microspheres of chitosan and pluronic F-127 for controlled release of 5-fluorouracil. J Microencapsul. 2007;24(3):274-288.
47. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly (isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials. 2007;28(13):2233-2243.
48. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 2002;233(1-2):51-59.
49. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002;19(10):1488-1494.
50. Shekels LL, Lyftogt CT, Ho SB. Bile acid-induced alterations of mucin production in differentiated human colon cancer cell lines* 1. Int J Biochem Cell Biol. 1996;28(2):193-201.
51. Niv Y, Byrd JC, Ho SB, Dahiya R, Kim YS. Mucin synthesis and secretion in relation to spontaneous differentiation of colon cancer cells in vitro. Int J Cancer. 1992;50(1):147-152.
52. Prego C, Fabre M, Torres D, Alonso M. Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm Res. 2006;23(3):549-556.